Construction of Mouse Model of Polycystic Ovary Syndrome

doi:10.12280/gjfckx.20210970

Abstract

Abstract:

Polycystic ovary syndrome（PCOS） is considered to be one of the most common female endocrine diseases with complex etiology and high incidence rate. Its diverse clinical manifestations and long-term complications seriously affect the physical and mental health and quality of life of patients. Therefore, the establishment of a practical and effective experimental model is very important to the research of PCOS. Rats and mice are one of the most commonly used experimental animals because of their small size, short reproductive cycle and stable estrous cycle. This paper reviews the research progress of mouse models of PCOS at home and abroad based on the clinical characteristics, hormone levels, endocrine and metabolic indexes of PCOS, aims to evaluate the advantages and disadvantages of various models and provide guidance for the selection of models in experiments.

Key words: Polycystic ovary syndrome, Disease models,animal, Muridae, Gene editing, Review

HUANG Qian-qian, WANG Jiao-jian, SONG Dian-rong. Construction of Mouse Model of Polycystic Ovary Syndrome[J]. Journal of International Obstetrics and Gynecology, 2022, 49(3): 261-266.

Figures/Tables 1

References 41

[1]	Li T, Zhang T, Gao H, et al. Tempol ameliorates polycystic ovary syndrome through attenuating intestinal oxidative stress and modulating of gut microbiota composition-serum metabolites interaction[J]. Redox Biol, 2021, 41:101886. doi: 10.1016/j.redox.2021.101886. doi: 10.1016/j.redox.2021.101886
[2]	Marshall CJ, Prescott M, Campbell RE. Investigating the NPY/AgRP/GABA to GnRH Neuron Circuit in Prenatally Androgenized PCOS-Like Mice[J]. J Endocr Soc, 2020, 4(11): bvaa129. doi: 10.1210/jendso/bvaa129. doi: 10.1210/jendso/bvaa129
[3]	Kupreeva M, Diane A, Lehner R, et al. Effect of metformin and flutamide on insulin,lipogenic and androgen-estrogen signaling,and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model[J]. Am J Physiol Endocrinol Metab, 2019, 316(1):E16-E33. doi: 10.1152/ajpendo.00018.2018. doi: 10.1152/ajpendo.00018.2018
[4]	Senaldi L, Gopi RP, Milla S, et al. Is ultrasound useful in the diagnosis of adolescents with polycystic ovary syndrome?[J]. J Pediatr Endocrinol Metab, 2015, 28(5/6):605-612. doi: 10.1515/jpem-2014-0307. doi: 10.1515/jpem-2014-0307
[5]	Crisosto N, Ladrón de Guevara A, Echiburú B, et al. Higher luteinizing hormone levels associated with antimüllerian hormone in postmenarchal daughters of women with polycystic ovary syndrome[J]. Fertil Steril, 2019, 111(2):381-388. doi: 10.1016/j.fertnstert.2018.10.011. doi: S0015-0282(18)32099-5 pmid: 30527840
[6]	Barker DJ. The fetal and infant origins of adult disease[J]. BMJ, 1990, 301(6761):1111. doi: 10.1136/bmj.301.6761.1111. doi: 10.1136/bmj.301.6761.1111
[7]	O′Reilly MW, Kempegowda P, Walsh M, et al. AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome[J]. J Clin Endocrinol Metab, 2017, 102(9):3327-3339. doi: 10.1210/jc.2017-00947. doi: 10.1210/jc.2017-00947
[8]	Risal S, Pei Y, Lu H, et al. Prenatal androgen exposure and transgenerational susceptibility to polycystic ovary syndrome[J]. Nat Med, 2019, 25(12):1894-1904. doi: 10.1038/s41591-019-0666-1. doi: 10.1038/s41591-019-0666-1
[9]	Moore AM, Prescott M, Campbell RE. Estradiol negative and positive feedback in a prenatal androgen-induced mouse model of polycystic ovarian syndrome[J]. Endocrinology, 2013, 154(2):796-806. doi: 10.1210/en.2012-1954. doi: 10.1210/en.2012-1954
[10]	Wu XY, Li ZL, Wu CY, et al. Endocrine traits of polycystic ovary syndrome in prenatally androgenized female Sprague-Dawley rats[J]. Endocr J, 2010, 57(3):201-209. doi: 10.1507/endocrj.k09e-205. doi: 10.1507/endocrj.k09e-205
[11]	Caldwell AS, Eid S, Kay CR, et al. Haplosufficient genomic androgen receptor signaling is adequate to protect female mice from induction of polycystic ovary syndrome features by prenatal hyperandrogenization[J]. Endocrinology, 2015, 156(4):1441-1452. doi: 10.1210/en.2014-1887. doi: 10.1210/en.2014-1887 pmid: 25643156
[12]	Dewailly D, Barbotin AL, Dumont A, et al. Role of Anti-Müllerian Hormone in the Pathogenesis of Polycystic Ovary Syndrome[J]. Front Endocrinol (Lausanne), 2020, 11:641. doi: 10.3389/fendo.2020.00641. doi: 10.3389/fendo.2020.00641
[13]	Tata B, Mimouni NEH, Barbotin AL, et al. Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood[J]. Nat Med, 2018, 24(6):834-846. doi: 10.1038/s41591-018-0035-5. doi: 10.1038/s41591-018-0035-5
[14]	Stener-Victorin E, Padmanabhan V, Walters KA, et al. Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome[J]. Endocr Rev, 2020, 41(4):538-576. doi: 10.1210/endrev/bnaa010. doi: 10.1210/endrev/bnaa010
[15]	Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone[J]. Anat Rec, 1991, 231(2):185-192. doi: 10.1002/ar.1092310206. doi: 10.1002/ar.1092310206 pmid: 1836118
[16]	张晓薇, 邝健全. 脱氢表雄酮诱导多囊卵巢综合征动物模型的研究[J]. 广州医学院学报, 2000, 28(3):14-18. doi: 10.3969/j.issn.1008-1836.2000.03.005. doi: 10.3969/j.issn.1008-1836.2000.03.005
[17]	Divyashree S, Janhavi P, Ravindra PV, et al. Experimental models of polycystic ovary syndrome: An update[J]. Life Sci, 2019, 237:116911. doi: 10.1016/j.lfs.2019.116911. doi: 10.1016/j.lfs.2019.116911
[18]	盛哲津, 石嘉豪, 严惠敏, 等. 丙酸睾酮致小鼠多囊卵巢综合症动物模型的建立[J]. 实验动物与比较医学, 2013, 33(5):334-338. doi: 10.3969/j.issn.1674-5817.2013.05.002. doi: 10.3969/j.issn.1674-5817.2013.05.002
[19]	Azeemuddin M, Anturlikar SD, Onkaramurthy M, et al. Effect of "DXB-2030," a Polyherbal Formulation,on Experimental Polycystic Ovary Syndrome Associated with Hyperandrogenism[J]. Adv Pharmacol Sci,2019, 2019:8272850. doi: 10.1155/2019/8272850. doi: 10.1155/2019/8272850
[20]	Gao Z, Ma X, Liu J, et al. Troxerutin protects against DHT-induced polycystic ovary syndrome in rats[J]. J Ovarian Res, 2020, 13(1):106. doi: 10.1186/s13048-020-00701-z. doi: 10.1186/s13048-020-00701-z
[21]	Xue P, Wang Z, Fu X, et al. A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome[J]. J Vis Exp, 2018, 140:58379. doi: 10.3791/58379. doi: 10.3791/58379
[22]	Wang Z, Feng M, Awe O, et al. Gonadotrope androgen receptor mediates pituitary responsiveness to hormones and androgen-induced subfertility[J]. JCI Insight, 2019, 4(17):e127817. doi: 10.1172/jci.insight.127817. doi: 10.1172/jci.insight.127817
[23]	Fazel Torshizi F, Chamani M, Khodaei HR, et al. Therapeutic effects of organic zinc on reproductive hormones,insulin resistance and mTOR expression,as a novel component,in a rat model of Polycystic ovary syndrome[J]. Iran J Basic Med Sci, 2020, 23(1):36-45. doi: 10.22038/IJBMS.2019.36004.8586. doi: 10.22038/IJBMS.2019.36004.8586 pmid: 32405346
[24]	Anzai Á, Marcondes RR, Gonçalves TH, et al. Impaired branched-chain amino acid metabolism may underlie the nonalcoholic fatty liver disease-like pathology of neonatal testosterone-treated female rats[J]. Sci Rep, 2017, 7(1):13167. doi: 10.1038/s41598-017-13451-8. doi: 10.1038/s41598-017-13451-8
[25]	Walters KA, Allan CM, Handelsman DJ. Rodent models for human polycystic ovary syndrome[J]. Biol Reprod, 2012, 86(5):149,1-12. doi: 10.1095/biolreprod.111.097808. doi: 10.1095/biolreprod.111.097808
[26]	Kafali H, Iriadam M, Ozardali I, et al. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease[J]. Arch Med Res, 2004, 35(2):103-108. doi: 10.1016/j.arcmed.2003.10.005. doi: 10.1016/j.arcmed.2003.10.005 pmid: 15010188
[27]	Lian Y, Zhao F, Wang W. Use of Bao Gui capsule in treatment of a polycystic ovary syndrome rat model[J]. Mol Med Rep, 2020, 21(3):1461-1470. doi: 10.3892/mmr.2020.10953. doi: 10.3892/mmr.2020.10953
[28]	Torres PJ, Skarra DV, Ho BS, et al. Letrozole treatment of adult female mice results in a similar reproductive phenotype but distinct changes in metabolism and the gut microbiome compared to pubertal mice[J]. BMC Microbiol, 2019, 19(1):57. doi: 10.1186/s12866-019-1425-7. doi: 10.1186/s12866-019-1425-7 pmid: 30871463
[29]	Bogovich K. Induction of ovarian cysts in progesterone-synchronized immature rats: evidence that suppression of follicular aromatase activity is not a prerequisite for the induction of cystic follicles[J]. Endocrinology, 1989, 124(4):1646-1653. doi: 10.1210/endo-124-4-1646. doi: 10.1210/endo-124-4-1646 pmid: 2924717
[30]	朱辉, 倪江, 姚兰春, 等. 大鼠多囊卵巢动物模型的实验研究[J]. 哈尔滨医科大学学报, 1999, 33(3):187-188.
[31]	Poretsky L, Piper B. Insulin resistance,hypersecretion of LH,and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome[J]. Obstet Gynecol, 1994, 84(4):613-621. doi: 10.1016/0020-7292(95)90027-6. doi: 10.1016/0020-7292(95)90027-6 pmid: 8090402
[32]	Hong G, Wu H, Ma ST, et al. Catechins from oolong tea improve uterine defects by inhibiting STAT3 signaling in polycystic ovary syndrome mice[J]. Chin Med, 2020, 15(1):125. doi: 10.1186/s13020-020-00405-y. doi: 10.1186/s13020-020-00405-y
[33]	Ajmal N, Khan SZ, Shaikh R. Polycystic ovary syndrome (PCOS) and genetic predisposition: A review article[J]. Eur J Obstet Gynecol Reprod Biol X, 2019, 3:100060. doi: 10.1016/j.eurox.2019.100060. doi: 10.1016/j.eurox.2019.100060
[34]	Ryan GE, Malik S, Mellon PL. Antiandrogen Treatment Ameliorates Reproductive and Metabolic Phenotypes in the Letrozole-Induced Mouse Model of PCOS[J]. Endocrinology, 2018, 159(4):1734-1747. doi: 10.1210/en.2017-03218. doi: 10.1210/en.2017-03218
[35]	Marino JS, Iler J, Dowling AR, et al. Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation[J]. PLoS One, 2012, 7(10):e48643. doi: 10.1371/journal.pone.0048643. doi: 10.1371/journal.pone.0048643
[36]	Khan MJ, Ullah A, Basit S. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives[J]. Appl Clin Genet, 2019, 12:249-260. doi: 10.2147/TACG.S200341. doi: 10.2147/TACG.S200341
[37]	Risma KA, Clay CM, Nett TM, et al. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility,polycystic ovaries,and ovarian tumors[J]. Proc Natl Acad Sci U S A, 1995, 92(5):1322-1326. doi: 10.1073/pnas.92.5.1322. doi: 10.1073/pnas.92.5.1322 pmid: 7877975
[38]	Liu Y, Du SY, Ding M, et al. The BMP4-Smad signaling pathway regulates hyperandrogenism development in a female mouse model[J]. J Biol Chem, 2017, 292(28):11740-11750. doi: 10.1074/jbc.M117.781369. doi: 10.1074/jbc.M117.781369
[39]	Baldissera SF, Motta LD, Almeida MC, et al. Proposal of an experimental model for the study of polycystic ovaries[J]. Braz J Med Biol Res, 1991, 24(7):747-751. doi: 10.1007/BF02175102. doi: 10.1007/BF02175102 pmid: 1823293
[40]	Ruiz A, Aguilar R, Tébar AM, et al. RU486-treated rats show endocrine and morphological responses to therapies analogous to responses of women with polycystic ovary syndrome treated with similar therapies[J]. Biol Reprod, 1996, 55(6):1284-1291. doi: 10.1095/biolreprod55.6.1284. doi: 10.1095/biolreprod55.6.1284 pmid: 8949885
[41]	Ryu Y, Kim YJ, Kim YY, et al. Consecutive Low Doses of Streptozotocin Induce Polycystic Ovary Syndrome Features in Mice[J]. Int J Mol Sci, 2021, 22(3):1299. doi: 10.3390/ijms22031299. doi: 10.3390/ijms22031299

造模方法	造模用药	鼠别	鼠龄	给药方式	剂量（时间）	造模周期（d）
雄激素造模法	DHEA	SD大鼠	23日龄	皮下注射	6 mg/100 g	20
	DHT	Wistar大鼠	5~9日龄	皮下注射	1.25 mg	35
	TP	SD大鼠	21日龄	皮下注射	2.5~10 mg	90
雌激素造模法	EV	SD大鼠	4~5周龄	皮下注射	2~4 mg	28
	EB	Wistar大鼠	2日龄	皮下注射	0.5 mg	90
芳香化酶抑制剂造模法	来曲唑	SD大鼠	6周龄	灌胃	1 mg/kg	21
孕激素造模法	孕激素+hCG	SD大鼠	23~24日龄	皮下埋植+皮下注射	左旋18-甲基炔诺酮硅胶棒3 mm/只+ hCG 1.5 IU/次,2次/d	12
胰岛素造模法	胰岛素+hCG	SD大鼠	6周龄	皮下注射	1.5~6.0 IU/d hCG+ 0.5~6 IU INS	22

造模方法	造模用药	鼠别	鼠龄	给药方式	剂量（时间）	造模周期（d）
雄激素造模法	DHEA	SD大鼠	23日龄	皮下注射	6 mg/100 g	20
	DHT	Wistar大鼠	5~9日龄	皮下注射	1.25 mg	35
	TP	SD大鼠	21日龄	皮下注射	2.5~10 mg	90
雌激素造模法	EV	SD大鼠	4~5周龄	皮下注射	2~4 mg	28
	EB	Wistar大鼠	2日龄	皮下注射	0.5 mg	90
芳香化酶抑制剂造模法	来曲唑	SD大鼠	6周龄	灌胃	1 mg/kg	21
孕激素造模法	孕激素+hCG	SD大鼠	23~24日龄	皮下埋植+皮下注射	左旋18-甲基炔诺酮硅胶棒3 mm/只+ hCG 1.5 IU/次,2次/d	12
胰岛素造模法	胰岛素+hCG	SD大鼠	6周龄	皮下注射	1.5~6.0 IU/d hCG+ 0.5~6 IU INS	22